Viewing Opinion | StockChase
Abbott Labs (ABT-N) opinion on 2012-11-30

Last Price Recorded: 55.5600 on 2017-11-17

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical
TOP PICK

Chyanne Fickes
Abbott Labs was $65.000 at time of opinion
Owned : Yes

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

CAUTIOUS

All opinions for ABT-N (106)

30 BUY
5 BUY on WEAKNESS
17 COMMENT
7 DON'T BUY
6 HOLD
14 PAST TOP PICK
1 SELL
1 SELL ON STRENGTH
23 TOP PICK
2 WAIT
View All

More experts covering ABT-N

SAVE
Add ABT-N to Watch List

All opinions for ABT-N (106)

30 BUY
5 BUY on WEAKNESS
17 COMMENT
7 DON'T BUY
6 HOLD
14 PAST TOP PICK
1 SELL
1 SELL ON STRENGTH
23 TOP PICK
2 WAIT
View All

More experts covering ABT-N

SAVE
Add ABT-N to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company